By Gary M. White, MD

The BRAF mutation inhibitor, vemurafenib, is approved for the treatment of adults with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Reported Cutaneous Side Effects


Multiple milia JAAD Oct 2013

KA induced by vemurafenib. British Journal of Dermatology 2015;172: 540–542


Homepage | FAQs | Contact Dr. White

It is not the intention of to provide specific medical advice, diagnosis or treatment. only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.